The vascular tumor growth model proposed by Pinho et al. has gained attention in studies of the effect of anti–angiogenic therapy. In the present work, we extend Pinho's model to a reaction-diffusion model with different cell growth behaviors to evaluate the individual and combined effects of chemotherapy, anti–angiogenic therapy, and immunotherapy across different stages of vascular cancer. Analysis of the model includes the existence and stability of up to six different equilibria with bifurcations that define the transitions between them. By establishing conditions for the stability of the cancer-free equilibrium, we numerically explore different dynamics of cancer relapse. This includes examining the timing and frequency of relapse and identifying thresholds for critical treatment parameters. Furthermore, the numerical simulations of the extended model show that in the advanced stages of cancer, the integration of chemotherapy, immunotherapy, and anti–angiogenic therapy is essential for effective control of vascular cancer and reduces the overall duration of treatment.
Citation: Priscilla Owusu Sekyere, Majid Bani-Yaghoub, Bi-Botti C. Youan. Reaction-diffusion modeling of vascular tumor growth: Bifurcation, relapse, and therapy efficacy[J]. Mathematical Biosciences and Engineering, 2025, 22(11): 2944-2987. doi: 10.3934/mbe.2025109
The vascular tumor growth model proposed by Pinho et al. has gained attention in studies of the effect of anti–angiogenic therapy. In the present work, we extend Pinho's model to a reaction-diffusion model with different cell growth behaviors to evaluate the individual and combined effects of chemotherapy, anti–angiogenic therapy, and immunotherapy across different stages of vascular cancer. Analysis of the model includes the existence and stability of up to six different equilibria with bifurcations that define the transitions between them. By establishing conditions for the stability of the cancer-free equilibrium, we numerically explore different dynamics of cancer relapse. This includes examining the timing and frequency of relapse and identifying thresholds for critical treatment parameters. Furthermore, the numerical simulations of the extended model show that in the advanced stages of cancer, the integration of chemotherapy, immunotherapy, and anti–angiogenic therapy is essential for effective control of vascular cancer and reduces the overall duration of treatment.
| [1] |
K. E. de Visser, J. A. Joyce, The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth, Cancer Cell, 41 (2023), 424–446. https://doi.org/10.1016/j.ccell.2023.02.016 doi: 10.1016/j.ccell.2023.02.016
|
| [2] |
T. Azizi, Mathematical modelling of cancer treatments, resistance, optimization, AppliedMath, 5 (2025), 40. https://doi.org/10.3390/appliedmath5020040 doi: 10.3390/appliedmath5020040
|
| [3] | A. Hernández-Rivera, P. Velarde, A. Zafra-Cabeza, J. M. Maestre, A stochastic model predictive control approach to deal with cancerous tumor growth, in 2023 9th International Conference on Control, Decision and Information Technologies (CoDIT), IEEE, (2023), 2037–2042. https://doi.org/10.1109/CoDIT58514.2023.10284136 |
| [4] |
C. Antonescu, Malignant vascular tumors—An update, Mod. Pathol., 27 (2014), S30–S38. https://doi.org/10.1038/modpathol.2013.171 doi: 10.1038/modpathol.2013.171
|
| [5] |
T. A. Partanen, K. Paavonen, Lymphatic versus blood vascular endothelial growth factors and receptors in humans, Microsc. Res. Tech., 55 (2001), 108–121. https://doi.org/10.1002/jemt.1174 doi: 10.1002/jemt.1174
|
| [6] |
X. Shi, X. Wang, W. Yao, D. Shi, X. Shao, Z. Lu, et al., Mechanism insights and therapeutic intervention of tumor metastasis: Latest developments and perspectives, Cell. Mol. Life Sci., 9 (2024), 192. https://doi.org/10.1007/s00018-024-05267-w doi: 10.1007/s00018-024-05267-w
|
| [7] | E. Sadeghi, I. Zamani, Z. G. Zarandi, S. T. Afshari, Finite-time fuzzy control design for drug dosage delivery in cancer treatment, in 2021 7th International Conference on Control, Instrumentation and Automation (ICCIA), IEEE, (2021), 1–6. https://doi.org/10.1109/ICCIA52082.2021.9403530 |
| [8] |
L. Hanum, N. Susyanto, D. Ertiningsih, Mathematical model of the impact of chemotherapy and anti-angiogenic therapy on drug resistance in glioma growth, Comput. Math. Biophys., 13 (2023), 20250022. https://doi.org/10.1515/cmb-2025-0022 doi: 10.1515/cmb-2025-0022
|
| [9] |
S. Sujitha, T. Jayakumar, D. Maheskumar, E. V. Kaviyan, Mathematical model of brain tumor with radiotherapy treatment, Commun. Math. Appl., 14 (2023), 1039–1050. https://doi.org/10.26713/cma.v14i2.2442 doi: 10.26713/cma.v14i2.2442
|
| [10] |
S. Sujitha, T. Jayakumar, D. Maheskumar, Fractional model of brain tumor with chemo-radiotherapy treatment, J. Appl. Math. Comput., 69 (2023), 3793–3818. https://doi.org/10.1007/s12190-023-01935-6 doi: 10.1007/s12190-023-01935-6
|
| [11] |
S. Sujitha, T. Jayakumar, D. Maheskumar, E. V. Kaviyan, An analytical and numerical approach to chemo-radiotherapy model for the treatment of brain tumor, OPSEARCH, 2024 (2024), 1–26. https://doi.org/10.1007/s12597-024-00670-9 doi: 10.1007/s12597-024-00670-9
|
| [12] |
E. V. Kaviyan, T. Jayakumar, S. Sujitha, D. Maheskumar, Analytical and numerical solutions for glial cells interactions between immunotherapy and cancer cells, Commun. Math. Appl., 14 (2023), 925–935. https://doi.org/10.26713/cma.v14i2.2465 doi: 10.26713/cma.v14i2.2465
|
| [13] |
S. Sharma, G. P. Samanta, Dynamical behaviour of a tumor-immune system with chemotherapy and optimal control, J. Nonlinear Dyn., 2013 (2013), 608598. https://doi.org/10.1155/2013/608598 doi: 10.1155/2013/608598
|
| [14] |
E. S. Ghasemabad, I. Zamani, H. Tourajizadeh, M. Mirhadi, Z. G. Zarandi, Design and implementation of an adaptive fuzzy sliding mode controller for drug delivery in treatment of vascular cancer tumours and its optimisation using genetic algorithm tool, IET Syst. Biol., 16 (2022), 345–355. https://doi.org/10.1049/syb2.12051 doi: 10.1049/syb2.12051
|
| [15] |
S. T. R. Pinho, F. S. Bacelar, R. F. S. Andrade, H. I. Freedman, A mathematical model for the effect of anti-angiogenic therapy in the treatment of cancer tumours by chemotherapy, Nonlinear Anal. Real World Appl., 14 (2013), 815–828. https://doi.org/10.1016/j.nonrwa.2012.07.022 doi: 10.1016/j.nonrwa.2012.07.022
|
| [16] |
P. De Luca, A. Galletti, G. Giunta, L. Marcellino, A numerical approach for a 1D tumor-angiogenesis simulations model, Appl. Numer. Math., 210 (2025), 83–94. https://doi.org/10.1016/j.apnum.2024.11.017 doi: 10.1016/j.apnum.2024.11.017
|
| [17] |
I. Lampropoulos, M. Koutsi, M. E. Kavousanakis, Modeling of chemo-radiotherapy targeting growing vascular tumors: A continuum-level approach, PLoS One, 20 (2025), e0301657. https://doi.org/10.1371/journal.pone.0301657 doi: 10.1371/journal.pone.0301657
|
| [18] |
M. Kuznetsov, A. Kolobov, Antiangiogenic therapy efficacy can be tumor-size dependent, as mathematical modeling suggests, Mathematics, 12 (2024), 353. https://doi.org/10.3390/math12020353 doi: 10.3390/math12020353
|
| [19] |
D. S. Santurio, L. R. C. Barros, A mathematical model for on-target off-tumor effect of CAR-T cells on gliomas, Front. Syst. Biol., 2 (2022), 923085. https://doi.org/10.3389/fsysb.2022.923085 doi: 10.3389/fsysb.2022.923085
|
| [20] |
P. Khalili, S. Zolatash, R. Vatankhah, S. Taghvaei, Optimal control methods for drug delivery in cancerous tumour by anti-angiogenic therapy and chemotherapy, IET Syst. Biol., 15 (2021), 13–24. https://doi.org/10.1049/syb2.12010 doi: 10.1049/syb2.12010
|
| [21] |
S. E. Haout, M. Fatani, N. A. Farha, N. AlSawaftah, M. Mortula, G. A. Husseini, Modeling the effects of chemotherapy and immunotherapy on tumor growth, J. Biomed. Nanotechnol., 17 (2021), 2505–2518. https://doi.org/10.1166/jbn.2021.3214 doi: 10.1166/jbn.2021.3214
|
| [22] |
E. Urenda-Cázares, A. Gallegos, J. E. Macías-Díaz, A mathematical model that combines chemotherapy and oncolytic virotherapy as an alternative treatment against a glioma, J. Math. Chem., 58 (2020), 544–554. https://doi.org/10.1007/s10910-019-01070-8 doi: 10.1007/s10910-019-01070-8
|
| [23] |
G. P. Samanta, R. G. Aíza, S. Sharma, Analysis of a mathematical model of periodically pulsed chemotherapy treatment, Int. J. Dyn. Control, 5 (2017), 842–857. https://doi.org/10.1007/s40435-015-0204-2 doi: 10.1007/s40435-015-0204-2
|
| [24] |
D. S. Rodrigues, P. F. A. Mancera, S. T. R. Pinho, Understanding the antiangiogenic effect of metronomic chemotherapy through a simple mathematical model, Physica A, 464 (2016), 251–266. https://doi.org/10.1016/j.physa.2016.07.027 doi: 10.1016/j.physa.2016.07.027
|
| [25] |
D. Li, W. Ma, S. Guo, Stability of a mathematical model of tumour-induced angiogenesis, Nonlinear Anal. Model. Control, 21 (2016), 325–344. https://doi.org/10.15388/NA.2016.3.3 doi: 10.15388/NA.2016.3.3
|
| [26] |
R. T. Guiraldello, M. L. Martins, P. F. A. Mancera, Evaluating the efficacies of maximum tolerated dose and metronomic chemotherapies: A mathematical approach, Math. Biosci., 275 (2016), 19–26. https://doi.org/10.1016/j.mbs.2016.03.004 doi: 10.1016/j.mbs.2016.03.004
|
| [27] |
M. Peleg, M. G. Corradini, M. D. Normand, The logistic (Verhulst) model for sigmoid microbial growth curves revisited, Food Res. Int., 40 (2007), 808–818. https://doi.org/10.1016/j.foodres.2007.01.012 doi: 10.1016/j.foodres.2007.01.012
|
| [28] |
C. Letellier, S. K. Sasmal, C. Draghi, F. Denis, D. Ghosh, A chemotherapy combined with an anti-angiogenic drug applied to a cancer model including angiogenesis, Chaos Solitons Fractals, 104 (2017), 252–263. https://doi.org/10.1016/j.chaos.2017.04.013 doi: 10.1016/j.chaos.2017.04.013
|
| [29] |
D. A. Hormuth, C. M. Phillips, C. Wu, E. A. Lima, G. Lorenzo, P. K. Jha, et al., Biologically-based mathematical modeling of tumor vasculature and angiogenesis via time-resolved imaging data, Cancers, 13 (2021), 3008. https://doi.org/10.3390/cancers13123008 doi: 10.3390/cancers13123008
|
| [30] |
J. S. Spratt, J. A. Meyer, Rates of growth of human neoplasms: part Ⅱ, J. Surg. Oncol., 61 (1996), 68–83. https://doi.org/10.1002/1096-9098(199601)61:1<68::AID-JSO2930610102>3.0.CO;2-E doi: 10.1002/1096-9098(199601)61:1<68::AID-JSO2930610102>3.0.CO;2-E
|
| [31] | B. Alberts, A. Johnson, J. Lewis, M. Raff, K. Roberts, P. Walter, Molecular Biology of the Cell, Taylor & Francis Books, 2002. |
| [32] |
D. Hanahan, J. Folkman, Patterns and emerging mechanisms of the angiogenic switch during tumourigenesis, Cell, 86 (1996), 353–364. https://doi.org/10.1016/S0092-8674(00)80108-7 doi: 10.1016/S0092-8674(00)80108-7
|
| [33] | R. T. Silver, R. D. Lauper, C. I. Jarowski, A Synopsis of Cancer Chemotherapy, Yorke Medical Books, 1987. |
| [34] | T. Browder, C. E. Butterfield, B. M. Kraling, B. Shi, B. Marshall, M. S. O'Reilly, et al., Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res., 60 (2001), 1878–1886. |
| [35] |
R. Said, M. Abdel-Rehim, B. Sadeghia, S. Al-Hashemi, Z. Hassana, M. Hassan, Cyclophosphamide pharmacokinetics in mice: A comparison between retro orbital sampling versus serial tail vein bleeding, Open Pharmacol. J., 1 (2007), 30–35. https://doi.org/10.2174/1874143600701010030 doi: 10.2174/1874143600701010030
|
| [36] | S. Shusterman, S. A. Grupp, R. Barr, D. Carpentieri, H. Zhao, J. M. Maris, The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth especially in the setting of subclinical disease, Clin. Cancer Res., 7 (2001), 977–984. |
| [37] | J. Trobia, K. Tian, A. M. Batista, C. Grebogi, H. P. Ren, M. S. Santos, et al., Mathematical model of brain tumour growth with drug resistance, preprint, arXiv: 2012.08252. |
| [38] |
J. Rieth, S. Subramanian, Mechanisms of intrinsic tumor resistance to immunotherapy, Int. J. Mol. Sci., 19 (2018), 1340. https://doi.org/10.3390/ijms19051340 doi: 10.3390/ijms19051340
|
| [39] |
S. Yonucu, D. Yilmaz, C. Phipps, M. B. Unlu, M. Kohandel, Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy, PLoS Comput. Biol., 13 (2017), e1005724. https://doi.org/10.1371/journal.pcbi.1005724 doi: 10.1371/journal.pcbi.1005724
|
| [40] | X. Shi, X. He, X. Ou, Model of tumor growth and treatment with anti-angiogenesis therapy and immunotherapy, in 2015 4th International Conference on Computer Science and Network Technology (ICCSNT), IEEE, (2015), 62–66. https://doi.org/10.1109/ICCSNT.2015.7491025 |
| [41] |
M. K. Pugsley, R. Tabrizchi, The vascular system: An overview of structure and function, J. Pharmacol. Toxicol. Methods, 44 (2000), 333–340. https://doi.org/10.1016/S1056-8719(00)00125-8 doi: 10.1016/S1056-8719(00)00125-8
|
| [42] |
O. Trédan, C. M. Galmarini, K. Patel, I. F. Tannock, Drug resistance and the solid tumor microenvironment, J. Natl. Cancer Inst., 99 (2007), 1441–1454. https://doi.org/10.1093/jnci/djm135 doi: 10.1093/jnci/djm135
|
| [43] | R. A. Stahel, S. Peters, Successes and Limitations of Targeted Cancer Therapy, Karger Medical and Scientific Publishers, 2014. https://doi.org/10.1159/isbn.978-3-318-02542-2 |
| [44] |
M. Broecker-Preuss, S. Müller, M. Britten, K. Worm, K. W. Schmid, K. Mann, et al., Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status, BMC Cancer, 15 (2015), 1–13. https://doi.org/10.1186/s12885-015-1186-0 doi: 10.1186/s12885-015-1186-0
|
| [45] |
Y. Zhang, G. Li, X. Liu, Y. Song, J. Xie, G. Li, et al., Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells, Oncol. Lett., 15 (2018), 5620–5626. https://doi.org/10.3892/ol.2018.8010 doi: 10.3892/ol.2018.8010
|
| [46] |
D. Morgensztern, S. Waqar, J. Subramanian, F. Gao, K. Trinkaus, R. Govindan, Prognostic significance of tumor size in patients with Stage Ⅲ non–small-cell lung cancer: A surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003, J. Thorac. Oncol., 7 (2012), 1479–1484. https://doi.org/10.1097/JTO.0b013e318267d032 doi: 10.1097/JTO.0b013e318267d032
|
| [47] |
E. F. Patz Jr, S. Rossi, D. H. Harpole Jr, J. E. Herndon, P. C. Goodman, Correlation of tumor size and survival in patients with Stage ⅠA non-small cell lung cancer, Chest, 117 (2000), 1568–1571. https://doi.org/10.1378/chest.117.6.1568 doi: 10.1378/chest.117.6.1568
|
| [48] |
F. Yang, H. Chen, J. Xiang, Y. Zhang, J. Zhou, H. Hu, et al., Relationship between tumor size and disease stage in non-small cell lung cancer, BMC Cancer, 10 (2010), 474. https://doi.org/10.1186/1471-2407-10-474 doi: 10.1186/1471-2407-10-474
|
| [49] |
P. Ciciola, P. Cascetta, C. Bianco, L. Formisano, R. Bianco, Combining immune checkpoint inhibitors with anti-angiogenic agents, J. Clin. Med., 9 (2020), 873. https://doi.org/10.3390/jcm9030675 doi: 10.3390/jcm9030675
|
| [50] |
A. Andreozzi, M. Iasiello, P. A. Netti, The effects of exterior boundary conditions on a internally heated tumor tissue with a thermoporoelastic model, J. Biomech., 113 (2020), 110122. https://doi.org/10.1016/j.jbiomech.2020.110122 doi: 10.1016/j.jbiomech.2020.110122
|
| [51] |
Y. Zhuang, S. Cui, Analysis of a free boundary problem modeling the growth of spherically symmetric tumors with angiogenesis, Acta Appl. Math., 161 (2019), 153–169. https://doi.org/10.1007/s10440-019-00236-w doi: 10.1007/s10440-019-00236-w
|
| [52] |
J. Wang, H. Zheng, Y. Jia, H. K. Xu, Spatial patterns and bifurcation analysis of a diffusive tumour-immune model, Taiwanese J. Math., 25 (2021), 553–577. https://doi.org/10.11650/tjm/200904 doi: 10.11650/tjm/200904
|
| [53] |
K. K. Menta, M. Bani-Yaghoub, B. B. C. Youan, Uncovering dual oscillatory regimes in p53-mdm2 dynamics: A data-driven modeling approach with implications for cancer progression, BioSystems, 2025 (2025), 105540. https://doi.org/10.1016/j.biosystems.2025.105540 doi: 10.1016/j.biosystems.2025.105540
|
| [54] | M. Bani-Yaghoub, D. E. Amundsen, Turing-type instabilities in a mathematical model of notch and retinoic acid pathways, 2006. Available from: https://mospace.umsystem.edu/xmlui/handle/10355/66819. |
| [55] |
A. Yin, D. J. A. Moes, J. G. van Hasselt, J. J. Swen, H. J. Guchelaar, A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors, CPT Pharmacometrics Syst. Pharmacol., 8 (2019), 720–737. https://doi.org/10.1002/psp4.12450 doi: 10.1002/psp4.12450
|
| [56] |
C. A. Valentim Jr., N. A. Oliveira, J. A. Rabi, S. A. David, Can fractional calculus help improve tumor growth models, J. Comput. Appl. Math., 379 (2020), 112964. https://doi.org/10.1016/j.cam.2020.112964 doi: 10.1016/j.cam.2020.112964
|
| [57] |
E. Ucar, N. Özdemir, E. Altun, Fractional order model of immune cells influenced by cancer cells, Math. Model. Nat. Phenom., 14 (2019), 308. https://doi.org/10.1051/mmnp/2019002 doi: 10.1051/mmnp/2019002
|
| [58] |
S. Khajanchi, J. J. Nieto, Mathematical modeling of tumor-immune competitive system, considering the role of time delay, Appl. Math. Comput., 340 (2019), 180–205. https://doi.org/10.1016/j.amc.2018.08.018 doi: 10.1016/j.amc.2018.08.018
|
| [59] |
P. Unni, P. Seshaiyer, Mathematical modeling, analysis, and simulation of tumor dynamics with drug interventions, Comput. Math. Methods Med., 2019 (2019), 4079298. https://doi.org/10.1155/2019/4079298 doi: 10.1155/2019/4079298
|
| [60] |
H. Y. Liu, H. L. Yang, L. G. Yang, Dynamics analysis in a tumor-immune system with chemotherapy, Chin. Phys. B, 30 (2021), 058201. https://doi.org/10.1088/1674-1056/abcf49 doi: 10.1088/1674-1056/abcf49
|
| [61] |
F. Subhan, M. A. Aziz, J. A. Shah, K. A. Kadir, I. M. Qureshi, Tumor treatment protocol by using genetic algorithm based Bernstein polynomials and sliding mode controller, IEEE Access, 9 (2021), 150192–150205. https://doi.org/10.1109/ACCESS.2021.3126491 doi: 10.1109/ACCESS.2021.3126491
|
| [62] |
K. C. Iarosz, F. S. Borges, A. M. Batista, M. S. Baptista, R. A. N. Siqueira, R. L. Viana, et al., Mathematical model of brain tumour with glia–neuron interactions and chemotherapy treatment, J. Theor. Biol., 368 (2015), 113–121. https://doi.org/10.1016/j.jtbi.2015.01.006 doi: 10.1016/j.jtbi.2015.01.006
|
| [63] | J. Malinzi, R. Ouifki, A. Eladdadi, D. F. M. Torres, K. A. J. White, Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis, preprint, arXiv: 1807.04329v1. |
| [64] |
S. Khajanchi, M. Sardar, J. J. Nieto, Application of non-singular kernel in a tumor model with strong Allee effect, Differ. Equations Dyn. Syst., 31 (2023), 687–692. https://doi.org/10.1007/s12591-022-00622-x doi: 10.1007/s12591-022-00622-x
|
| [65] |
S. Sharma, G. P. Samanta, Analysis of the dynamics of a tumor–immune system with chemotherapy and immunotherapy and quadratic optimal control, Differ. Equations Dyn. Syst., 24 (2016), 149–171. https://doi.org/10.1007/s12591-015-0250-1 doi: 10.1007/s12591-015-0250-1
|
| [66] |
J. M. J. da Costa, H. R. B. Orlande, W. B. da Silva, Model selection and parameter estimation in tumor growth models using approximate Bayesian computation-ABC, Comput. Appl. Math., 37 (2017), 1–14. https://doi.org/10.1007/s40314-017-0479-0 doi: 10.1007/s40314-017-0479-0
|
| [67] |
D. S. Rodrigues, P. F. A. Mancera, Mathematical analysis and simulations involving chemotherapy and surgery on large human tumours under a suitable cell-kill functional response, Math. Biosci. Eng., 10 (2013), 221–234. https://doi.org/10.3934/mbe.2013.10.221 doi: 10.3934/mbe.2013.10.221
|
| [68] |
L. G. Parajdi, R. Precup, M. A. Şerban, I. Ş. Haplea, Analysis of the effectiveness of the treatment of solid tumors in two cases of drug administration, Math. Biosci. Eng., 18 (2021), 1845–1863. https://doi.org/10.3934/mbe.2021096 doi: 10.3934/mbe.2021096
|
| [69] |
L. Berezansky, E. Braverman, L. Idels, Effect of treatment on the global dynamics of delayed pathological angiogenesis models, Math. Biosci., 259 (2014), 34–48. https://doi.org/10.1016/j.mbs.2014.08.002 doi: 10.1016/j.mbs.2014.08.002
|
| [70] |
M. Alanazi, M. Bani-Yaghoub, B. B. C. Youan, Stable periodic solutions of a delayed reaction-diffusion model of Hes1-mRNA interactions, Math. Biosci. Eng., 22 (2025), 2152–2175. https://doi.org/10.3934/mbe.2025079 doi: 10.3934/mbe.2025079
|
| [71] |
O. Akinjole, K. Menta, A. Alsalhi, M. Bani-Yaghoub, B. B. C. Youan, Novel Meta-iodobenzylguanidine and Etoposide complex: Physicochemical characterization and mathematical modeling of anticancer activity, AAPS PharmSciTech, 24 (2023), 174. https://doi.org/10.1208/s12249-023-02599-4 doi: 10.1208/s12249-023-02599-4
|
| [72] |
M. Bani-Yaghoub, C. Ou, G. Yao, Delay-induced instabilities of stationary solutions in a single species nonlocal hyperbolic-parabolic population model, Discrete Contin. Dyn. Syst., 13 (2020), 2509–2535. https://doi.org/10.3934/dcdss.2020195 doi: 10.3934/dcdss.2020195
|
| [73] | M. Bani-Yaghoub, Analysis and applications of delay differential equations in biology and medicine, preprint, arXiv: 1701.04173. |
| [74] | M. Bani-Yaghoub, Introduction to delay models and their wave solutions, preprint, arXiv: 1701.04703. |
| [75] |
M. Bani-Yaghoub, D. E. Amundsen, Dynamics of notch activity in a model of interacting signaling pathways, Bull. Math. Biol., 72 (2010), 780–804. https://doi.org/10.1007/s11538-009-9469-8 doi: 10.1007/s11538-009-9469-8
|
| [76] | M. A. Bani-Yaghoub, D. E. Amundsen, The role of Retinoic Acid and Notch in the symmetry breaking instabilities for axon formation, in International Conference on Mathematical Biology, World Scientific and Engineering Academy and Society (WSEAS), 2006. |
Figures(14) / Tables(6)
Priscilla Owusu Sekyere, Majid Bani-Yaghoub, Bi-Botti C. Youan. Reaction-diffusion modeling of vascular tumor growth: Bifurcation, relapse, and therapy efficacy[J]. Mathematical Biosciences and Engineering, 2025, 22(11): 2944-2987. doi: 10.3934/mbe.2025109
DownLoad: